Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares

Rhea-AI Summary

Bicycle Therapeutics plc (Nasdaq: BCYC) has priced a public offering of 3,240,741 American Depositary Shares (ADSs) at $54.00 each, aiming for gross proceeds of $175.0 million. The underwriters have a 30-day option to purchase an additional 486,111 ADSs. Proceeds will be utilized for advancing its product pipeline and for research and development. The offering is set to close on or around October 15, 2021, pending customary conditions. Goldman Sachs, Morgan Stanley, and SVB Leerink are managing the offering.

Positive

• Gross proceeds of $175 million will support product pipeline advancement.
• Plans to utilize funds for R&D and general corporate purposes enhance growth potential.

Negative

• Potential shareholder dilution from the offering of ADSs.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million. In addition, Bicycle has granted the underwriters in the offering a 30-day option to purchase up to 486,111 additional ADSs at the public offering price. The offering is expected to close on or about October 15, 2021, subject to customary closing conditions.

Bicycle plans to use the net proceeds from the offering to advance its proprietary product pipeline and for other research and development, as well as for general corporate purposes.

Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink are acting as joint book-running managers for the offering. JMP Securities is acting as co-manager for the offering.

The offering is being made pursuant to a “shelf” registration statement on Form S-3 that was filed by Bicycle with the Securities and Exchange Commission (“SEC”) and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement, final prospectus supplement and accompanying prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; or SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements relating to Bicycle’s expectations regarding the completion of the offering, the expected gross proceeds from the offering and Bicycle’s planned use of the proceeds from the public offering. These forward-looking statements are based on Bicycle’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Bicycle will be able to complete the offering on the anticipated terms, or at all. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Bicycle’s filings with the SEC, including under the heading “Risk Factors” contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Except as required by law, Bicycle assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006262/en/

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617-203-8300

Source: Bicycle Therapeutics plc

FAQ

What is the purpose of Bicycle Therapeutics' recent public offering?

Bicycle Therapeutics plans to use the proceeds from the offering to advance its product pipeline and for research and development, as well as for general corporate purposes.

How much did Bicycle Therapeutics raise from the recent offering?

Bicycle Therapeutics raised gross proceeds of $175.0 million from the public offering.

What is the price of the ADSs in Bicycle Therapeutics' offering?

Each American Depositary Share (ADS) in the offering is priced at $54.00.

Who are the underwriters for Bicycle Therapeutics' offering?

Goldman Sachs, Morgan Stanley, and SVB Leerink are acting as joint book-running managers for the offering.